Home › Funds › DCF Advisers, LLC › LFCR
DCF Advisers, LLC position in LFCR
LIFECORE BIOMEDICAL INC · Health Care
DCF Advisers, LLC reported holding 376,500 shares of LFCR (LIFECORE BIOMEDICAL INC) in its Q3 2026 13F filing — a position valued at US$2.5M, representing 0.73% of its reported portfolio and ranking #34 among its reported holdings. DCF Advisers, LLC has disclosed LFCR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How DCF Advisers, LLC's LFCR position evolved
DCF Advisers, LLC first disclosed a stake in LFCR in Q3 2023 at 120,754 shares (US$911K). The position peaked in Q4 2024 at 539,989 shares, worth US$4.0M. Across 13 filings, DCF Advisers, LLC increased the stake 4 time(s), trimmed it 7 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 376,500 shares valued at US$2.5M — a reduction of -48,000 shares quarter over quarter.. Notable position changes include a 115% increase in Q4 2023 (shares fell 14% over the following quarter), a 87% increase in Q4 2024 (shares fell 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 120.75K | $911.09K | New |
| Q4 2023 | 259.68K | $1.61M | Add |
| Q1 2024 | 284.68K | $1.51M | Add |
| Q2 2024 | 290.68K | $1.49M | Add |
| Q3 2024 | 288.48K | $1.42M | Reduce |
| Q4 2024 | 539.99K | $4.01M | Add |
| Q1 2025 | 483.00K | $3.40M | Reduce |
| Q2 2025 | 462.99K | $3.76M | Reduce |
| Q3 2025 | 452.00K | $3.33M | Reduce |
| Q4 2025 | 442.00K | $3.62M | Reduce |
| Q1 2026 | 424.50K | $1.58M | Reduce |
| Q2 2026 | 424.50K | $2.23M | Hold |
| Q3 2026 | 376.50K | $2.48M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LFCR and 13F data
LFCR (LIFECORE BIOMEDICAL INC) is a Health Care company. 21 other funds we track also report a position in LFCR — the largest reported positions include WYNNEFIELD CAPITAL INC (US$24.7M), Legion Partners Asset Management, LLC (US$23.4M), Greenhaven Road Investment Management, L.P. (US$16.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LFCR
- WYNNEFIELD CAPITAL INC 4.70M sh · $24.69M · Q2 2026
- Legion Partners Asset Management, LLC 4.46M sh · $23.42M · Q2 2026
- Greenhaven Road Investment Management, L.P. 3.19M sh · $16.75M · Q2 2026
- 325 CAPITAL LLC 2.90M sh · $15.20M · Q2 2026
- WITTENBERG INVESTMENT MANAGEMENT, INC. 314.01K sh · $1.65M · Q2 2026
More on DCF Advisers, LLC
FAQ
How long has DCF Advisers, LLC held LFCR?
DCF Advisers, LLC has disclosed LFCR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is DCF Advisers, LLC's current position in LFCR?
As of Q3 2026, DCF Advisers, LLC holds 376.50K shares of LFCR (LIFECORE BIOMEDICAL INC), valued at $2.48M, representing 0.73% of its reported portfolio and ranking #34.
Has DCF Advisers, LLC been buying or selling LFCR?
In the latest 13F filing (Q3 2026), DCF Advisers, LLC reduced its position in LFCR. The position peaked in Q4 2024 at 539.99K shares.
Which other funds hold LFCR?
Other major institutional holders of LFCR include WYNNEFIELD CAPITAL INC, Legion Partners Asset Management, LLC, Greenhaven Road Investment Management, L.P., among 21 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.